These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12202961)

  • 1. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data.
    Agelink MW; Ullrich H; Baumann B; Strum S; Majewski T
    Psychopharmacology (Berl); 2002 Sep; 163(2):151-6. PubMed ID: 12202961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia.
    Ferini-Strambi L; Manconi M; Castronovo V; Riva L; Bianchi A
    J Psychopharmacol; 2004 Sep; 18(3):417-22. PubMed ID: 15358987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
    Burrows GD; Maguire KP; Norman TR
    J Clin Psychiatry; 1998; 59 Suppl 14():4-7. PubMed ID: 9818623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
    Dekeyne A; Gobert A; Iob L; Cistarelli L; Melon C; Millan MJ
    Psychopharmacology (Berl); 2001 Nov; 158(2):213-8. PubMed ID: 11702096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action.
    Page ME; Brown K; Lucki I
    Psychopharmacology (Berl); 2003 Jan; 165(2):194-201. PubMed ID: 12426668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine.
    Fossa AA; Wisialowski TA; Cremers T; van der Hart M; Tseng E; Deng S; Rollema H; Wang EQ
    Toxicol Appl Pharmacol; 2012 Nov; 264(3):343-50. PubMed ID: 23000177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional-structural model to understand cardiac autonomic nervous system (ANS) dysregulation in affective illness and to elucidate the ANS effects of antidepressive treatment.
    Agelink MW; Klimke A; Cordes J; Sanner D; Kavuk I; Malessa R; Klieser E; Baumann B
    Eur J Med Res; 2004 Jan; 9(1):37-50. PubMed ID: 14766337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of noradrenergic re-uptake inhibition on memory encoding in man.
    Papps BP; Shajahan PM; Ebmeier KP; O'Carroll RE
    Psychopharmacology (Berl); 2002 Jan; 159(3):311-8. PubMed ID: 11862364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition.
    Tank J; Schroeder C; Diedrich A; Szczech E; Haertter S; Sharma AM; Luft FC; Jordan J
    Circulation; 2003 Jun; 107(23):2949-54. PubMed ID: 12796139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
    Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
    Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of reboxetine in bulimia nervosa: a pilot study.
    Fassino S; Daga GA; Boggio S; Garzaro L; Pierò A
    J Psychopharmacol; 2004 Sep; 18(3):423-8. PubMed ID: 15358988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report.
    Lerner AG; Shufman E; Kodesh A; Kretzmer G; Sigal M
    Isr J Psychiatry Relat Sci; 2002; 39(2):100-3. PubMed ID: 12227224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of reboxetine in healthy male volunteers.
    Denolle T; Pellizzoni C; Jannuzzo MG; Poggesi I
    Clin Pharmacol Ther; 1999 Sep; 66(3):282-7. PubMed ID: 10511064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
    Hajós M; Fleishaker JC; Filipiak-Reisner JK; Brown MT; Wong EH
    CNS Drug Rev; 2004; 10(1):23-44. PubMed ID: 14978512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.